Gene expression profiling of treated and untreated primary prostate cancer

In clinical trials assessing neoadjuvant androgen deprivation therapy plus next-generation androgen receptor axis inhibitors, a subset of patients fail to demonstrate a complete pathologic response following treatment and radical prostatectomy. We performed transcriptome analyses on laser capture microdissected foci of residual tumor from these patients. This study consists of 3 control (untreated) samples of primary prostate cancer and 19 samples of prostate cancer treated with neoadjuvant androgen deprivation therapy.